x
ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2019 > Eastern Europe and Balkan Region Refresher Course on Gastro-intestinal Cancer
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Eastern Europe and Balkan Region Refresher Course on Gastro-intestinal Cancer

9 ESCO credits

17.10.2019  -  19.10.2019

Zagreb, Croatia

COURSES AND SEMINARS

Gastro-intestinal tumours

Description

Chair: D. Papamichael, CY


The Refresher Course on Gastrointestinal Cancer is designed for medical and clinical oncologists of the Eastern Europe and Balkan Region in order to provide an update on the state-of-the-art therapeutic options as well as an overview of the latest advances in the field of Gastro intestinal cancer.
The programme will offer educational lectures covering updates and future directions in diagnostic and treatment approaches in Gastrointestinal cancer; while real life case discussions will provide an ideal opportunity for multidisciplinary discussion. By presenting real life cases young oncologist will get an ideal opportunity to learn on how to best present and discuss their cases.
Attendance to the course is limited and by application only. Priority will be given to applicants who have attended a previous Eastern Europe and Balkan Region Masterclass

LEARNING OBJECTIVES
• Update on the latest advances and the state-of-the-art treatment options
• Learn about the management of specific situations
• Debate controversies and challenges in gastro-intestinal cancer treatment
• Improve practical skills in multidisciplinary management and follow-up of gastro-intestinal cancer

Faculty

INVITED FACULTY
B. Belev, University Hospital Center, Zagreb, HR
F. Bibeau, Caen University Hospital, Pathology Department, Caen, FR
S. Cascinu, University of Modena and Reggio Emilia, IT
R. Glynne Jones, Mount Vernon Hospital, Watford and Barnet General Hospitals in London, UK
A. Juretic, University Hospital "Sveti Duh", Zagreb, HR
T. Omrcen, University Hospital of Split, Split, HR
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY
J. Souglakos, University of Crete, School of Medicine, Heraklion, GR
P. Tekkis, The Royal Marsden Hospital, London, UK

General information

ORGANISING SECRETARIAT
European School of Oncology (ESO)
Piazza Indipendenza 2
6500 Bellinzona
Laura Richetti,
ph +41 91 820 09 51, e-mail: lrichetti@eso.net

OFFICIAL LANGUAGE
The official language will be English. No translation will be available.

CME ACCREDITATION
The Eastern Europe and Balkan Region Refresher Course on Gastro-Intestinal Cancer is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
It has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 8 European CME credits (ECMEC®s).
Each medical specialist should claim only those credits that he/she actually spent in the educational activity.
The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



Application

PARTICIPATION
Applicants who have not attended a previous EEBR Masterclass should meet the following profile:

• Age between 30 and 40 years
• At least 2-3 years’ experience in medical oncology
• Fluency in English.

Successful applicants are granted free registration, lunches and coffee breaks as from Programme.
Free accommodation at the course venue (two nights) will be provided to participants not residing in the Zagreb area.

Priority will be given to applicants who have attended a previous Eastern Europe and Balkan Region Masterclass.

The application outcome will be notified by e-mail by Middle of July.

ATTENDANCE TO THE MASTERCLASS IS LIMITED AND BY APPLICATION ONLY
THE APPLICATION DEADLINE HAS PASSED (22 JUNE 2019)

Programme

 

17 October

18:00 Registration
20:00 Welcome dinner

18 October

 
8:15 Welcome and introduction
A. Eniu, RO - D. Papamichael, CY
COLON CANCER  
8:30 Histopathological and Molecular staging of colon cancer
F. Bibeau, FR
9:00 Optimal management of stage II and III colon cancer
J. Souglakos, GR
9:30 Review of the ESMO consensus conference for mCRC
J. Souglakos, GR
10:00 Best approach for the management of oligometastatic disease
D. Papamichael, CY
10:30 Coffee break
11:00 Liquid biopsy - potential uses in CRC
D. Papamichael, CY
11:30 Optimal management of ‘liver only’ mCRC
B. Belev, HR
12:00 Tumor board: Selected clinical cases presented by participants and discussed with the faculty
13:00 Lunch
RECTAL CANCER
14:00 Pre-operative management of rectal cancer - state of the art
R. Glynne Jones, UK
14:30 The use of chemotherapy in rectal cancer - current controversies
R. Glynne Jones, UK
15:00 Coffee break
15:30 Optimal staging of rectal cancer and management implications
P. Tekkis, UK
16:00 Surgical aspects and management pitfalls in non-metastatic rectal cancer
P. Tekkis, UK
16:30 Tumor board: Selected clinical cases presented by participants and discussed with the faculty

19 October

GASTRIC CANCER  
9:00 First line therapy and beyond
T. Omrcen, HR
9:30 Optimal peri-operative therapy for localised gastric/GEJ cancer
S. Cascinu, IT
10:00 Molecular classification of gastric cancer - ready for prime time?
S. Cascinu, IT
10:30 The role of immunotherapy in Gastric Cancer
A. Juretic, HR
11:00 Closing remarks
D. Papamichael, CY